Study Title
A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer
Study Details
Description:
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours.
Sponsor:
Telix PharmaceuticalsContacts:
Julie Gisbonjulie.gibson@telixpharma.com
317-588-9700
Charlotte Hawkins, PhDcharlotte.hawkins@telixpharma.com
317-588-9700
Government Study Link:
NCT05146973 - Click here to see study onClinicalTrials.gov
- Biochemical relapse (serum >0.2ng/mL)
- At least one pelvic nodal lesion >=5mm
- Oligometastatic disease (<=5 metastatic lymph nodes)
- Chemotherapy naive
- Previous radical prostatectomy with curative intent
- Bone or visceral metastases
- Androgen deprivation therapy within 12 months of trial screening
- History of any malignancy other than prostate cancer within 5 years of enrolment
Patient Education
Patient Education Not Yet Provided
Publications
Locations
Not yet provided. Contact Julie Gisbon for more information.
317-588-9700
julie.gibson@telixpharma.com
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468